CD3-directed Antibody Interactions

CD3 Receptor Agonists

Bispecific CD19-directed CD3-directed T Cell Engager

CD19-directed Antibody Interactions

Leukemia, Lymphoid

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-10"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">Blinatumomab is a bispecific CD19-directed CD3 T-cell engager. Blinatumomab is produced in Chinese hamster ovary cells. It consists of 504 amino acids and has a molecular weight of approximately 54 kilodaltons.</p><p>Each BLINCYTO package contains 1 vial BLINCYTO and 1 vial IV Solution Stabilizer.</p><p>BLINCYTO (blinatumomab) for injection is supplied in a single-dose vial as a sterile, preservative-free, white to off-white lyophilized powder for intravenous use. Each single-dose vial of BLINCYTO contains 35 mcg blinatumomab, citric acid monohydrate (3.35 mg), lysine hydrochloride (23.23 mg), polysorbate 80 (0.64 mg), trehalose dihydrate (95.5 mg), and sodium hydroxide to adjust pH to 7.0. After reconstitution with 3 mL of preservative-free Sterile Water for Injection, USP, the resulting concentration is 12.5 mcg/mL blinatumomab.</p><p>IV Solution Stabilizer is supplied in a single-dose vial as a sterile, preservative-free, colorless to slightly yellow, clear solution. Each single-dose vial of IV Solution Stabilizer contains citric acid monohydrate (52.5 mg), lysine hydrochloride (2283.8 mg), polysorbate 80 (10 mg), sodium hydroxide to adjust pH to 7.0, and water for injection.</p></section>

BLINCYTO

blinatumomab

blinatumomab 0.035 MG Injection

Blincyto

blinatumomab 0.035 MG Injection [Blincyto]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event

Prescribing Information 

Medication Guide 

Pharmacy List 

Reimbursement Information 

Benefits Verification & PA Form 

Billing & Coding Guide 

Coverage Authorization Request 

Coverage Authorization Appeals 

Letter of Medical Necessity 

Enroll in Patient Savings Program 

About Blincyto: Relapsed or Refractory CD19-positive B-cell Precursor ALL

About Blincyto (Pediatrics): Relapsed or Refractory CD19-positive B-cell Precursor ALL

Receiving Blincyto: Relapsed or Refractory CD19-positive B-cell Precursor ALL

Instructions For Use: Relapsed or Refractory CD19-positive B-cell Precursor ALL

MRD Testing Facilities 

About Blincyto: Minimal Residual Disease (+) ALL

About Blincyto (Pediatrics): Minimal Residual Disease (+) ALL

Receiving Treatment: Minimal Residual Disease (+) ALL

Instructions For Use: Minimal Residual Disease (+) ALL

Patient Resources:  Minimal Residual Disease (+) ALL

Patient Brochure : Minimal Residual Disease (+) ALL

Patient Brochure: Minimal Residual Disease (+) ALL - Spanish 

Pediatric Patient Brochure: Minimal Residual Disease (+) ALL - Spanish 

Medication Information Card: Minimal Residual Disease (+) ALL

Medical Information Card: Minimal Residual Disease (+) ALL - Spanish 

Patient Resources: Relapsed or Refractory CD19-positive B-cell Precursor ALL

Patient Brochure: Relapsed or Refractory CD19-positive B-cell Precursor ALL - Spanish

Pediatric Patient Brochure: Relapsed or Refractory CD19-positive B-cell Precursor ALL - Spanish

Medical Information Card: Relapsed or Refractory CD19-positive B-cell Precursor ALL

Submit MSL Request 